APGE Secures $1.3B Strategic Financing from Blackstone, Advances Zumilokibart to Phase 3, $1.3B Total Cash Positioned for Self-Sustainability
Apogee Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $79.30
+20% in 1d after detection
Post-detection moves
1h
+13%
1d
+20%
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS